Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma (WindMIL-001)
Investigating Marrow Infiltrating Lymphocytes as a Source of Adoptive Cellular Therapy in Renal Cell Carcinoma and Urothelial Carcinoma
Sponsor: University of Oklahoma
Terminated
Study funding was withdrawn.
Other terminated trials from University of Oklahoma
Other Renal Cell Carcinoma trials with similar outcome
Listed as NCT04341740, this NA trial focuses on Renal Cell Carcinoma and Urothelial Carcinoma and remains terminated or withdrawn. Sponsored by University of Oklahoma, it has been updated 12 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2024 — Jul 2024 [monthly]
Terminated NA
-
Dec 2023 — Jan 2024 [monthly]
Terminated NA
-
Sep 2021 — Dec 2023 [monthly]
Terminated NA
Status: Recruiting → Terminated
▶ Show 7 earlier versions
-
Mar 2021 — Sep 2021 [monthly]
Recruiting NA
Phase: EARLY_PHASE1 → NA
-
Jan 2021 — Mar 2021 [monthly]
Recruiting EARLY_PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Recruiting EARLY_PHASE1
-
Sep 2020 — Nov 2020 [monthly]
Recruiting EARLY_PHASE1
-
Jul 2020 — Sep 2020 [monthly]
Recruiting EARLY_PHASE1
-
Jun 2020 — Jul 2020 [monthly]
Recruiting EARLY_PHASE1
Status: Suspended → Recruiting
-
May 2020 — Jun 2020 [monthly]
Suspended EARLY_PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Oklahoma
- WindMIL Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .